CPT code 55710 represents a transperineal, ultrasound-guided prostate biopsy that performs systematic sextant sampling alongside MRI–ultrasound fusion targeting of suspicious lesions. This procedure is increasingly used in diagnostic pathways for men with elevated prostate-specific antigen (PSA) or suspicious imaging because it combines systematic coverage of standard prostate regions with focused sampling of MRI-identified targets, improving detection of clinically significant prostate cancer while reducing sampling error.

Key payers considered in this national overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context and service delivery, payer coverage patterns, billing and coding considerations, and related codes. The publication highlights benchmarks for utilization and reimbursement trends where available, summarizes relevant policy updates affecting imaging–fusion biopsy coverage, and outlines common billing scenarios and documentation elements necessary for claims adjudication.

This summary is intended to inform payers, providers, and revenue cycle teams about the clinical role of 55710, typical sites of service, and the kinds of analyses and benchmarks contained in the full publication. Data not available in the input is noted where applicable in the detailed sections.